XVIVO.ST
XVIVO.ST
SE0004840718
Xvivo Perfusion AB
Loading chart...

Company Profile

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Related stocks

VITR.ST
VITR.ST • Sweden
Vitrolife AB
95.6 SEK
1.3B USD 1Y -33.5%
EUZ.DE
EUZ.DE • Germany
Eckert & Ziegler SE I
12.36 EUR
866.7M USD 1Y -30.5%
IBAB.BR
IBAB.BR • Belgium
ION BEAM APPLICATIONS
15.74 EUR
512.21M USD 1Y +41.7%
MCAP.ST
MCAP.ST • Sweden
MedCap AB
515 SEK
771.71M USD 1Y -13%
EKTA-B.ST
EKTA-B.ST • Sweden
Elekta AB ser. B
54.45 SEK
2.08B USD 1Y +8%
NOLA-B.ST
NOLA-B.ST • Sweden
Nolato AB ser. B
57.1 SEK
1.54B USD 1Y -6.9%
CHEMM.CO
CHEMM.CO • Denmark
ChemoMetec A/S
586.5 DKK
1.51B USD 1Y -19.9%
MED.SW
MED.SW • Switzerland
MEDARTIS N
82.4 CHF
1.24B USD 1Y -4%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
51.5% p.a.
Max Drawdown (5Y)
-70.2%
Sharpe Ratio (5Y)
-0.24
Beta Factor
1.47
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 76.7 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (51.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -71.4% in the extended horizon.
ende